Preparation, antimicrobial evaluation and mutagenicity of differently substituted [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2-imidazolyl]methanols

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 15, 1996, Pages 1781-1784

  Arredondo, Y ^a   Moreno Manas M ^a   Pleixats, R ^a   Palacin C ^b   Raga, M M ^b   Castello J M ^b   Ortiz, J A ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Centro de Investigaciones Farmaceuticos Grupo Ferrer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 TERT BUTYL 2 HYDROXYPHENYL 5 NITRO 1 METHYL 2 IMIDAZOLYLCARBINOL; ABUNIDAZOLE; ANTIINFECTIVE AGENT; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ABSCESS; ANAEROBIC BACTERIUM; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTAGENICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; REACTION ANALYSIS; SALMONELLA TYPHIMURIUM;

ANIMALIA; BACTERIA (MICROORGANISMS); SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 0030572485     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00317-4     Document Type: Article

References (22)

1. 1. For the synthesis and evaluation of nitroimidazoles see, for example: a) Cosar, C.; Crisan, C.; Horclois, R.; Jacob, R.M.; Robert, J.;Tchelitcheff, S.; Vaupré, R. Arzneim.-Forsch. 1966, 16, 23.
2. b) Butler, K.; Howes, H.L.; Lynch, J.E.; Pirie, D.K. J. Med. Chem. 1967, 10, 891.
3. c) Giraldi, P.N.; Mariotti, V.; Nannini, G.; Tolosini, G.P.; Dradi, E.; Logemann, W.; De Carneri, I.; Monti, G. Arzneim.-Forsch. 1970, 20, 52.
4. d) Hoffer, M.; Grunberg, E. J. Med. Chem. 1974, 17, 1019.
5. e) Winkelmann, E.; Raether, W.; Gebert, U.; Sinharay, A. Arzneim.-Forsch. 1977, 27, 2251.
6. f) Neville, M.C.; Verge, J.P. J. Med. Chem. 1977, 20, 946.
7. 2. Woogd, C.E. Mutation Research 1981, 86, 243.
8. 3. Edwards, D.I. "Nitroimidazole drugs-action and resistance mechanisms/Mechanisms of action" J. Antimicrob. Chemoth. 1993, 31, 9.
9. 4. Tessitore, P.T. Eur. Pat. 111, 657 (1983).
10. 5. Furlan, D. (Euroresearch S.r.L.). Eur. Pat. 535, 528 (1992).
11. 6. Sartori, G.; Maggi, R.; Bigi, F.; Arienti, A.; Porta, C.; Predieri, G. Tetrahedron 1994, 50, 10587 and references cited therein.
12. 7. Nagata, W.; Okada, K.; Aoki, T. Synthesis 1979, 365.
13. 8. Foguet R.; Moreno-Mañas, M.; Arredondo, Y.; Pleixats, R.; Raga, M.M.; Castelló, J.M.; Ortiz, J.A. Spanish Pat. 9500255 (1995).
14. 4: C, 65.78; H, 6.57; N, 10.96. Found: C, 65.92; H, 6.29; N, 10.59. The other compounds were similarly prepared. They were characterized by spectroscopic means and all of them presented correct elemental analysis.
15. 10. a) Shafiee, A.; Pirouzzadeh, B.; Ghasemian, F.; Parang, K. J. Heterocyclic Chem. 1992, 29, 1021.
16. b) Rufer, C.; Kessler, H.-J.; Schröder, E. J. Med. Chem. 1971, 14, 94.
17. 11. Y. Arredondo, M. Moreno-Mañas, R. Pleixats. Submitted.
18. 12. a) Ames, B.N.; McCann, J.; Yamasaki, E. Mut. Res. 1975, 31, 347.
19. b) Maron, D.M.; Ames, B.N. Mut. Res. 1983, 113, 173.
20. 13. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A2. National Committee for Clinical Laboratory Standards, Vilanova, Pa. 1991.
21. 3 while 1i was not effective.
22. oct, from Structures: Leo, A.J., Chem. Rev. 1993, 93, 1281. ClogP for 1i was 2.75 and for metronidazole was -0.70. The program also contains the experimental value (-0.02) of logP for metronidazole.